FDA Removes Key Limitation on the Use of Real-World Evidence in Regulatory Reviews

oncodaily - On December 15, 2025, the U.S. Food and Drug Administration (FDA) announced a significant update to its regulatory approach regarding the use of real-world evidence (RWE) in drug and medical […]

AI Summary: The FDA has dramatically loosened its long‐standing limitations on the use of real‐world evidence in regulatory reviews, signaling an era where big data may facilitate quicker approvals for innovative drugs. Officials are also urging early-phase trials reform to better capture real‐world outcomes.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA commissioner Marty Makary resigns amid mounting scrutiny / 19 days

FDA Abortion Pill Decisions Rooted in Science / 4 months

FDA Appoints Richard Pazdur to Lead Drug Division Amid Regulatory Shifts / 6 months

FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month

FDA approves leucovorin for rare folate disorder despite autism hype / 2 months

FDA launches individualized therapy framework for ultra-rare diseases / 3 months

FDA makes one pivotal trial the default for drug approvals / 3 months